Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.
ERNA has been the topic of several other reports. Weiss Ratings restated a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Friday, July 17th. Brookline Capital Markets started coverage on shares of Ernexa Therapeutics in a research note on Thursday, May 7th. They issued a “buy” rating and a $30.00 target price for the company. Finally, Zacks Research upgraded shares of Ernexa Therapeutics to a “hold” rating in a report on Monday, May 11th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $30.00.
Check Out Our Latest Research Report on ERNA
Ernexa Therapeutics Price Performance
Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($3.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.30) by ($0.10). As a group, research analysts anticipate that Ernexa Therapeutics will post -18.02 EPS for the current year.
Institutional Trading of Ernexa Therapeutics
An institutional investor recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP acquired a new position in Ernexa Therapeutics Inc. (NASDAQ:ERNA – Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned about 0.39% of Ernexa Therapeutics at the end of the most recent quarter. 70.55% of the stock is owned by institutional investors and hedge funds.
About Ernexa Therapeutics
Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.
Recommended Stories
- Five stocks we like better than Ernexa Therapeutics
- Albemarle’s Blowout Quarter Shows Why Lithium Still Matters
- Can DICK’S Turn Foot Locker Into a Winner?
- Why Dutch Bros Plunged Despite a Q2 Earnings Beat and Record Revenue
- Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of War
Receive News & Ratings for Ernexa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ernexa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
